Target intelligence / Profile preview

Gastrointestinal tract smooth muscle

Molecular classification
Other (Smooth muscle tissue; not a receptor, enzyme, transporter, or single protein)
01

Overview

Gastrointestinal tract smooth muscle refers to the muscle tissue lining the walls of the gastrointestinal (GI) tract, from the esophagus to the rectum. It is composed of spindle-shaped smooth muscle cells arranged in inner circular and outer longitudinal layers. The coordinated contractions of these muscle layers, regulated by the autonomic nervous system and local pacemaker cells (interstitial cells of Cajal), are essential for peristalsis and mixing, enabling the digestion and absorption of food and the movement of waste. GI smooth muscle responds to neurotransmitters, hormones, and mechanical stimuli, operating involuntarily. Abnormalities in function or regulation of this tissue underlie several GI motility disorders, but the tissue itself is not a molecular therapeutic target; rather, diverse molecular targets within or regulating this tissue are modulated for therapeutic effect[1][2][4][6][7][8]. "Gastrointestinal tract smooth muscle" is a tissue, not a canonical therapeutic target such as a receptor, channel, or enzyme. Drugs act upon many molecular targets within this tissue (e.g., muscarinic acetylcholine receptor M3, serotonin receptors, calcium channels), but not upon the smooth muscle tissue as a single entity[1][2][4][6]. The correct use for structured drug/discovery databases is to specify the particular molecular target (such as "muscarinic acetylcholine receptor M3" or "L-type calcium channel") relevant to GI smooth muscle, rather than the tissue type itself.

Other names
gastrointestinal smooth muscleGI tract smooth musclegut smooth muscle
02

Biological functions

Gastrointestinal motility (transport of food and waste)Peristalsis and mixing of luminal contentsMaintenance of sphincter tone and continenceResponse to neurotransmitters and hormones
03

Disease associations

Gastrointestinal motility disorders (e.g., constipation, diarrhea, irritable bowel syndrome)Obstructive bowel disordersDisorders with altered peristalsis (e.g., achalasia, gastroparesis)
04

Safety considerations

Drugs targeting GI smooth muscle can cause gastrointestinal dysmotility, e.g. constipation, diarrhea, abdominal crampingOff-target effects can include cardiovascular impact due to smooth muscle in blood vessels

Beyond the preview

Go deeper on Gastrointestinal tract smooth muscle.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gastrointestinal tract smooth muscle.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call